TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation ; volume:25 ; number:1 ; day:25 ; month:7 ; year:2024 ; pages:1-13 ; date:12.2024
BMC immunology ; 25, Heft 1 (25.7.2024), 1-13, 12.2024
- Urheber
-
Ota, Yosuke
Inagaki, Ryosaku
Nagai, Yasuhiro
Hirose, Yuko
Murata, Masashi
Yamamoto, Setsuko
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12865-024-00643-x
- URN
-
urn:nbn:de:101:1-2410102122085.333032053063
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ota, Yosuke
- Inagaki, Ryosaku
- Nagai, Yasuhiro
- Hirose, Yuko
- Murata, Masashi
- Yamamoto, Setsuko
- SpringerLink (Online service)
Ähnliche Objekte (12)
Deoxyguanosine is a TLR7 agonist
Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells
Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod
A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune
Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction
Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod
An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responses
dSP
Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes
T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
Deoxyguanosine is a TLR7 agonist
Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells
Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod
A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune
Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction
Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod
An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responses
dSP
Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes
T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
Deoxyguanosine is a TLR7 agonist
Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells
Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod
A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune
Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction
Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod
An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responses
dSP
Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes